Kubota Pharmaceutical Holdings Co. Ltd. (4596) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wakamoto Pharmaceutical Co., Ltd.

Kainos Laboratories, Inc.

Perseus Proteomics, Inc.

Solasia Pharma KK

Nippon Chemiphar Co., Ltd.

Pharmarise Holdings Corp.

Kubota Pharmaceutical Holdings Co. Ltd.

Renascience, Inc.

D. Western Therapeutics Institute, Inc.

BrightPath Biotherapeutics Co., Ltd.

Delta-Fly Pharma, Inc.

Why is Kubota Pharmaceutical Holdings Co. Ltd. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Negative results in Mar 26

NET SALES(Q) At JPY 4.69 MM has Fallen at -11.99%
RAW MATERIAL COST(Y) Grown by 24.06% (YoY)
DEBTORS TURNOVER RATIO(HY) Lowest at 6.68 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 14.29%, its profits have risen by 30%

Underperformed the market in the last 1 year

The stock has generated a return of 14.29% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 85.83%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kubota Pharmaceutical Holdings Co. Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Kubota Pharmaceutical Holdings Co. Ltd.

14.29%

-0.15

143.88%

Japan Nikkei 225

85.83%

3.09

27.80%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-10.80%

EBIT Growth (5y)

10.70%

EBIT to Interest (avg)

-173.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.87

EV to EBIT

-12.30

EV to EBITDA

-12.30

EV to Capital Employed

-116.30

EV to Sales

494.92

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-49.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at JPY -600 MM

NET PROFIT(HY)

Higher at JPY -553.18 MM

DEBT-EQUITY RATIO (HY)

Lowest at -105.57 %

INVENTORY TURNOVER RATIO(HY)

Highest at 3.51 times

-19What is not working for the Company

NET SALES(Q)

At JPY 4.69 MM has Fallen at -11.99%

RAW MATERIAL COST(Y)

Grown by 24.06% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.68 times

OPERATING PROFIT(Q)

Lowest at JPY -302.25 MM

PRE-TAX PROFIT(Q)

Lowest at JPY -312.13 MM

NET PROFIT(Q)

Lowest at JPY -312.13 MM

Here's what is working for Kubota Pharmaceutical Holdings Co. Ltd.

Operating Cash Flow

Highest at JPY -600 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JPY MM)

Debt-Equity Ratio

Lowest at -105.57 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 3.51 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Kubota Pharmaceutical Holdings Co. Ltd.

Net Sales

At JPY 4.69 MM has Fallen at -11.99%

over average net sales of the previous four periods of JPY 5.33 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY -312.13 MM has Fallen at -39.63%

over average net sales of the previous four periods of JPY -223.53 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Operating Profit

Lowest at JPY -302.25 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Pre-Tax Profit

Lowest at JPY -312.13 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit

Lowest at JPY -312.13 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

Net Profit

At JPY -312.13 MM has Fallen at -39.63%

over average net sales of the previous four periods of JPY -223.53 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

Debtors Turnover Ratio

Lowest at 6.68 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 24.06% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales